Immunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.

Immunocore Holdings plc announced that management will participate in multiple investor conferences in September 2026, including presentations at Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The company's lead product KIMMTRAK generated $115.9 million in Q2 2026 revenues, representing 18% year-over-year growth.

Immunocore announced updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and disease control rate of 52%. The 160 mcg dose was selected for the ongoing Phase 3 PRISM-MEL-301 trial. The drug demonstrated clinical benefit in difficult-to-treat subgroups including patients with primary PD-1 resistance and was generally well tolerated as monotherapy and in combination with pembrolizumab.

Immunocore reported Q1 2026 net sales of $106.7 million for KIMMTRAK, representing 14% year-over-year growth. The company presented landmark five-year overall survival data at AACR showing KIMMTRAK doubled the likelihood of being alive at five years (16% vs 8%) for HLA-A*02:01 positive metastatic uveal melanoma patients. The company maintains $845 million in cash and is advancing its pipeline including Phase 3 trials for cutaneous melanoma expansion and PRAME-targeted candidates.

Immunocore announced five-year overall survival data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma, showing 16% OS versus 8% in control arm. The drug doubled survival likelihood and demonstrated durability across poor prognostic subgroups, representing the longest follow-up for any T cell engager in solid tumors.

Immunocore Holdings plc announced that management will participate in multiple investor conferences in March 2026, including TD Cowen Healthcare Conference, Leerink Global Healthcare Conference, Barclays Global Healthcare Conference, UBS Biotech Summit, and Jefferies Biotech on the Beach Summit. The company will present its commercial-stage biotechnology platform and pipeline.

Immunocore Holdings plc announced it will report Q4 and full year 2025 financial results on February 25, 2026, followed by a teleconference and webcast. The commercial-stage biotechnology company is advancing its ImmTAX platform for cancer, infectious diseases, and autoimmune diseases, with KIMMTRAK approved for unresectable or metastatic uveal melanoma across multiple markets.

Immunocore announced that Executive Vice President of R&D Dr. David Berman will depart the company on February 27, 2026. Rather than seeking a direct replacement, the company will streamline its R&D structure by promoting Dr. Mohammed Dar (Chief Medical Officer) and Mark Moyer (Head of Regulatory Sciences) to Executive Vice President roles with expanded oversight of clinical development and regulatory strategies.

Immunocore announced Phase 1 trial results for IMC-I109V, a T cell receptor bispecific candidate targeting hepatitis B virus, showing promising dose-dependent HBsAg reduction and a generally manageable safety profile.

The article highlights three low-cost stocks with potential significant growth: a gold mining company, a footwear retailer, and a biotechnology firm developing cancer treatments, each with unique market opportunities and analyst perspectives.

Immunocore Plc reported Q2 2025 results with 30% revenue growth to $98.0 million, driven by KIMMTRAK sales. Despite revenue success, the company experienced a net loss and continued investing heavily in research and development across multiple clinical programs.

Immunocore's HIV functional cure candidate IMC-M113V showed promising safety and signals of dose-dependent viral control in a Phase 1/2 trial, with some patients maintaining viral suppression for up to 12 weeks after stopping antiretroviral treatment.